The phase II BYLieve study evaluated the combination of alpelisib with endocrine therapy (either fulvestrant or letrozole) in patients with PIK3Ca mutant luminal/HER2-negative breast cancer who had progressed on prior systemic therapy [12]. Here, ERBB2 is linked to breast cancer.